Prame and rhamm genes expression in acute myeloid leukemia /
Hala Tarek Fathi
Prame and rhamm genes expression in acute myeloid leukemia / فى حالات اللوكيميا الميلودية الحادةPrame and Rhamm دراسة مدى ظهور جينى Hala Tarek Fathi ; Supervised Laila A. M. Hegazy , Asmaa A. Abdelaal , Sara A. Labib - Cairo : Hala Tarek Fathi , 2013 - 169 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Most patients with acute myeloid leukemia who are younger than 60 years achieve complete remission after chemotherapy and / or SCT. However relapse with its high associated morbidity and mortality (5 years survival rate 50% ) still occurs. To improve the clinical outcome of AML patients leukemia associated antigens were suggested to be targets for immune therapies as an additional approach to chemotherapy and / or SCT
Acute myeloid leukemia Prame (preferentially expressed antigen of melanoma Tumor/leukemia associated antigens TAAs/LAAs
Prame and rhamm genes expression in acute myeloid leukemia / فى حالات اللوكيميا الميلودية الحادةPrame and Rhamm دراسة مدى ظهور جينى Hala Tarek Fathi ; Supervised Laila A. M. Hegazy , Asmaa A. Abdelaal , Sara A. Labib - Cairo : Hala Tarek Fathi , 2013 - 169 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Most patients with acute myeloid leukemia who are younger than 60 years achieve complete remission after chemotherapy and / or SCT. However relapse with its high associated morbidity and mortality (5 years survival rate 50% ) still occurs. To improve the clinical outcome of AML patients leukemia associated antigens were suggested to be targets for immune therapies as an additional approach to chemotherapy and / or SCT
Acute myeloid leukemia Prame (preferentially expressed antigen of melanoma Tumor/leukemia associated antigens TAAs/LAAs